Course: Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
CME Credits: 1.00
Released: 2021-12-01
Rituximab therapy has been associated with more severe COVID-19 infection in persons with multiple sclerosis,, although this finding was based on a small number of events. Further research is needed to evaluate the potential increased risk for severe disease. In this study, we examined the association between timing and dose of rituximab and hospitalization for COVID-19 across Sweden.
Educational Objective
To identify the key insights or developments described in this article
View Full Course